Royalty Pharma Announces 12% Dividend Increase
Royalty Pharma plc (Nasdaq: RPRX) announced a 12% increase in its quarterly dividend, now set at $0.19 per Class A share for Q1 2022. The dividend will be paid on March 15, 2022, to shareholders of record as of February 18, 2022. This reflects Royalty Pharma's ongoing commitment to returning value to its shareholders while leveraging its extensive portfolio of biopharmaceutical royalties.
- 12% increase in quarterly dividend to $0.19 per Class A share.
- Dividend payment reflects the company's commitment to shareholder value.
- None.
NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2022 of
The dividend will be paid on March 15, 2022, to shareholders of record at the close of business on February 18, 2022.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 40 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnson’s Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
What is the dividend amount declared by RPRX for Q1 2022?
When will the dividend be paid to shareholders of RPRX?
What is the record date for the RPRX dividend?
How much has RPRX increased its dividend?
